Is ARQT stock a buy?

• BUY — the filings support owning it.
• HOLD — fairly priced on the fundamentals; own it, don’t chase it.
• SELL — the filings argue for trimming or exiting.
• AVOID — we wouldn’t start a position here.

We re-rate when the company’s filings change, never the chart. Every change lands on the Flip Side and is scored on the live track record.

Is ARQT stock a buy right now?

Yes — our current verdict on Arcutis Biotherapeutics, Inc. (ARQT) is BUY (conviction 4 of 5): the SEC filings support owning it. The verdict was last set on June 25, 2026 and is re-evaluated nightly against Arcutis Biotherapeutics, Inc.'s SEC filings.

What is the TENK/calls verdict on ARQT based on?

Every verdict is reasoned over Arcutis Biotherapeutics, Inc.'s SEC XBRL fundamentals and filing history — revenue, margins, balance-sheet health and material 8-K events — plus the TENK Score quality composite. The cited figure behind the current call: Revenue $376M (FY2025). Ratings change only when the company's filings change, never on price action.

How often does the ARQT verdict update?

Calls are re-evaluated on a nightly cycle (Mon–Fri). A rating flips only when a filing fact changes the thesis — flips are tracked publicly on our rating-changes page and in the live track record.

Where can I see the full ARQT analysis?

The full Arcutis Biotherapeutics, Inc. page has the fundamentals, TENK Score, filings, events and peer comparison; the complete thesis with risks, catalysts and the price target is part of Pro.